Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTNASDAQ:OTICNASDAQ:PTIXNASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTConduit Pharmaceuticals$2.33-5.7%$6.59$2.31▼$2,707.50$1.86M2.02151,722 shs208,046 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/APTIXProtagenic Therapeutics$3.32-5.7%$3.83$2.35▼$15.82$1.96M0.36564,496 shs62,120 shsSHPHShuttle Pharmaceuticals$0.13-9.4%$6.10$0.12▼$4.30$1.46M-1.11.82 million shs3.99 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTConduit Pharmaceuticals0.00%-13.38%-61.93%-85.75%-99.93%OTICOtonomy0.00%0.00%0.00%0.00%0.00%PTIXProtagenic Therapeutics0.00%-8.29%+6.41%-10.14%-73.65%SHPHShuttle Pharmaceuticals-96.00%-97.10%-97.61%-98.56%+13,279,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDTConduit Pharmaceuticals0.2495 of 5 stars0.02.00.00.03.30.00.0OTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/APTIXProtagenic Therapeutics1.3109 of 5 stars0.04.00.00.04.11.70.0SHPHShuttle Pharmaceuticals0.7893 of 5 stars0.04.00.00.01.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTConduit Pharmaceuticals 4.00Strong BuyN/AN/AOTICOtonomy 0.00N/AN/AN/APTIXProtagenic Therapeutics 0.00N/AN/AN/ASHPHShuttle Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTConduit PharmaceuticalsN/AN/AN/AN/A($0.62) per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01PTIXProtagenic TherapeuticsN/AN/AN/AN/A$0.83 per shareN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$2.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTConduit Pharmaceuticals-$540K-$534.48N/A∞N/AN/AN/A-328.67%N/AOTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/APTIXProtagenic Therapeutics-$5M-$13.11N/A∞N/AN/A-308.97%-228.73%8/12/2025 (Estimated)SHPHShuttle Pharmaceuticals-$6.59M-$4.15N/A∞N/AN/A-583.02%-258.92%N/ALatest OTIC, CDT, PTIX, and SHPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CDTConduit PharmaceuticalsN/A-$19.80N/A-$1.32N/AN/A5/13/2025Q1 2025PTIXProtagenic TherapeuticsN/A-$2.75N/A-$2.75N/AN/A5/8/2025Q1 2025SHPHShuttle PharmaceuticalsN/A-$7.50N/A-$0.30N/AN/A3/31/2025Q4 2024PTIXProtagenic TherapeuticsN/A-$3.36N/A-$0.24N/AN/A3/28/2025Q4 2024CDTConduit PharmaceuticalsN/A-$304.95N/A-$20.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDTConduit PharmaceuticalsN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/APTIXProtagenic TherapeuticsN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTConduit PharmaceuticalsN/A0.120.12OTICOtonomyN/A1.741.74PTIXProtagenic TherapeuticsN/A1.801.80SHPHShuttle PharmaceuticalsN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTConduit Pharmaceuticals3.29%OTICOtonomy41.23%PTIXProtagenic Therapeutics7.97%SHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipCDTConduit Pharmaceuticals4.05%OTICOtonomy1.09%PTIXProtagenic Therapeutics35.00%SHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTConduit Pharmaceuticals3798,000710,000Not OptionableOTICOtonomy5168.53 million67.78 millionOptionablePTIXProtagenic Therapeutics2589,0004.71 millionNot OptionableSHPHShuttle Pharmaceuticals510.98 million2.46 millionNot OptionableOTIC, CDT, PTIX, and SHPH HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals Holdings Inc trading halted, news pendingJune 14 at 11:42 AM | msn.comShuttle Pharmaceuticals says reverse stock split to become effective June 16June 13 at 3:10 PM | finance.yahoo.comShuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern TimeJune 12 at 12:00 PM | globenewswire.comShuttle Pharmaceuticals Holdings, Inc. Proposes 25-for-1 Reverse Stock Split to Comply with Nasdaq RequirementsJune 12 at 8:56 AM | quiverquant.comShuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance InitiativeJune 12 at 8:30 AM | globenewswire.comShuttle Pharma Appoints George Scorsis Chairman of the Board of DirectorsJune 4, 2025 | globenewswire.comShuttle Pharmaceuticals slashes exec salaries by 70% as it fights to preserve cashMay 29, 2025 | bizjournals.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deShuttle Pharma Provides Corporate UpdateMay 15, 2025 | globenewswire.comShuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical TrialMay 8, 2025 | globenewswire.comShuttle Pharmaceuticals to Present Phase 2 Trial Update at Planet MicroCap Showcase: VEGAS 2025April 24, 2025 | nasdaq.comShuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025April 21, 2025 | globenewswire.comShuttle Pharmaceuticals files provisional patent application with USPTOApril 12, 2025 | markets.businessinsider.comShuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate CancerApril 10, 2025 | globenewswire.comShuttle Pharmaceuticals Appoints New Interim CEO and CSOMarch 31, 2025 | tipranks.comShuttle Pharmaceuticals Holdings, Inc. Closes $5.75 Million Public Offering to Fund Phase II Clinical TrialMarch 13, 2025 | quiverquant.comShuttle Pharma Announces Closing of $5.75 Million Underwritten OfferingMarch 13, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business ActivitiesMarch 12, 2025 | finanznachrichten.deShuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEOMarch 12, 2025 | markets.businessinsider.comShuttle Pharmaceuticals prices 19.17M shares at 30c per share in public offeringMarch 12, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingNVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the WaveBy Nathan Reiff | May 23, 2025View NVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the WaveNVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?By Leo Miller | May 20, 2025View NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?OTIC, CDT, PTIX, and SHPH Company DescriptionsConduit Pharmaceuticals NASDAQ:CDT$2.33 -0.14 (-5.67%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.40 +0.07 (+3.22%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.Protagenic Therapeutics NASDAQ:PTIX$3.32 -0.20 (-5.68%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.34 +0.02 (+0.45%) As of 06/13/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Shuttle Pharmaceuticals NASDAQ:SHPH$0.13 -0.01 (-9.35%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.13 0.00 (-1.36%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
